A rare case of acute myeloid leukemia with a CHIC2-ETV6 fusiongene and multiple other molecular aberrations Leukemia (2005) Acute myeloid leukemia (AML), like other human cancers, is the consequence of more than one mutation. Data from animal models of leukemia strongly support a multistep pathogenesis of the disease.
1 Chromosomal translocations most frequently target transcription factors involved in the regulation of normal hematopoietic differentiation, whereas molecular mutations often affect genes involved in signal transduction pathways associated with cell proliferation. Here, we present a case with multiple genetic and molecular defects targeting transcription factors as well as tyrosine kinases in a rare constellation.
A 39-year-old woman was referred to the hospital in July 2004 due to tonsillitis, hematomas and weakness. The laboratory data showed a white blood cell count of 39 000/ml with 85% blast cells, hemoglobin 7.1 g/dl and platelet count 70 000/ml. Bone marrow examination revealed 95% myeloblasts with little differentiation. The diagnosis was AML M1 according to FAB classification. Cytogenetic analysis of bone marrow cells revealed a t(4;12)(q12;p13) as well as a dic(7;12)(q11.2;p13). On the molecular level, the molecular correlate of the t(4;12)(q12;p13) a CHIC2-ETV6 fusion transcript could be demonstrated (Figure 1a, b) . In addition a FLT3 length mutation (FLT3-LM) (Figure 1c ), a mutation of NRAS codon 12 (Figure 1d ), MLL-PTD and a p53 mutation (TP53) (Figure 1e ) were detected. After being treated according to the German AMLCG study with HAM/HAM induction and TAD consolidation, the patient received allogenic bone marrow transplantation from her HLA matching sister in January 2005. The patient had a good initial response to chemotherapy as well as to transplantation and attained morphologic and cytogenetic remission until now. As target for minimal residual disease monitoring, the MLL-PTD was used, reflecting the clinical follow-up (Figure 1e ).
CHIC2 was initially described in the t(4;12)(q11;p13) translocation and is an in-frame fusion gene generated between CHIC2 (previously BTL) (exons 1-3) and the ETV6 gene (exons 2-8).
2 Probably due to its infrequent occurrence in AML no association with other mutations has been described yet. FLT3 length mutations (FLT3-LM) are frequently found in AML and are associated with a potentially worse prognosis. of 9% was detected, indicating that only a subclone was FLT3-LM positive in this case. NRAS mutations occur in approximately 11% of AML and can occur in almost all FAB subtypes. No influence on clinical outcome could be demonstrated until now. 5 In a recent study, RAS mutations occur up to 26% in AML and share similar pathways.
5
TP53 mutations are common abnormalities in AML with 5-15% and associated with older age and a worse prognosis. 6 However, TP53 mutations usually go along with a complex aberrant karyotype and were rarely or never described in combination with a reciprocal translocation.
7 Although mutations in FLT3, RAS and TP53 are one of the most frequent genetic alterations in AML, the coexistent occurrence of two or more of these mutations is very rare and presumably associated with a worse prognosis.
6,8 MLL partial tandem duplications (MLL-PTD) are present in 6.5% of AML.
9 Even though a possible synergistic role is not clear, an association of FLT3-LM and MLL-PTD was already described earlier.
10 Like the FLT3-LM, the MLL-PTD was only present in around 10% of all cells in this case but it could not be worked out whether it was the same clone that carried the FLT3-LM. Interestingly, MLL-fusion proteins seem to synergize with activated FLT3 and share a common role in the stepwise development of leukemia.
11 A functional association of MLL, RAS and TP53 has not been described yet.
Within the multistep development of AML the cooperation of different aberrations is necessary, but only rudimentary understood. This case is a good example for frequent occurring, partially synergizing mutations in AML involving activating mutations, point mutations and a mutation with unknown significance. Asparagine auxotrophy, which forms the basis for treatment of leukemia with L-asparaginase, (L-asp) has been shown in animal tumor cells to be related to the loss of expression of the enzyme Asparagine Synthetase (ASNS) (EC 6.3.5.4). 1 The extension of this concept to L-asp sensitivity in clinical cases of acute lymphoblastic leukaemia (ALL) has recently been challenged by the results of ASNS mRNA measurements in patients with t(12;21) translocations. The methodology favoured for measuring ASNS expression has been quantitative real-time PCR (qRT-PCR).
2-4
This technique presents numerous difficulties in application, particularly in the normalization of results and the use of reference genes, as recently reviewed.
5 Indeed, using variations of the method, a number of workers have drawn differing conclusions from studies of leukemic cells in short-term culture and in marrow specimens. [2] [3] [4] In addition, an examination of the mRNA and genomic sequences for ASNS shows additional factors that could contribute to the uncertainty. We therefore propose a simplified method for this assay in which these features are taken into account.
In the first place, there is the probability of inaccuracy due to a high degree of contamination with genomic DNA. This is a particular problem with small biological samples of varied nucleic acid content and in which there may only be a few copies of message.
5 To preferentially amplify mRNA, primers are selected that bridge intronic sequences or are located across a splice junction. However, genomic DNA contains processed pseudogenes (PCgs), which lack introns ( Figure 1a ) and can be amplified as a product indistinguishable from cDNA ( Figure 1b,  lanes 1-3) . This is the case for ASNS (3 PCgs) but even more so for the commonly used genes of reference, GAPDH (B20 PCgs) and b-actin (B9 PCgs). With large numbers of PCgs, as in the case of reference genes, design of specific primers or of specific probe sequences is extremely difficult and published methods have not usually accomplished this. Furthermore, if an amplification step is used before microarray analysis, the same problem can occur. It is possible prior to qRT-PCR analysis to remove genomic DNA by DNaseI treatment, but this results in a loss of mRNA (Figure 1b , lanes 8-9 and 17-18) even when the recombinant enzyme DNA-freet (Ambion) is used.
A second factor that must be taken into account with ASNS is the expression of at least three variant transcripts with alternative initial exons (Figure 2 ). Since it is not known whether differential expression may occur under varying circumstance, primers must include all transcripts. In recent studies by Stams et al 2 and Irino et al 3 the primers would amplify specifically from the consensus region of the three transcript variants. However, BLAST analysis against the human genome sequence indicates a significant potential for amplification from the PCg (on Chr18). The fragment generated is of the same size as that produced from mRNA and has almost exact homology in the region to which the probe anneals. In addition, in both cases expression levels where normalized against GAPDH, with more than 20 PCgs. Again, the primers used would generate a product capable of probe hybridization. To ensure that amplification is exclusively from mRNA and not PCg contamination a noreverse transcription (RT) control should be used with every sample. Alternatively, Krejci recently employed a technique that circumvented the PCg problem by careful design of ASNS primers and use of b2-microglobin.
4 However, as b2-microglobin has a variable expression pattern it has been suggested that it may not be effective as a reference gene. 6 We therefore demonstrate the use of a recently published method that permits the use of common reference genes and takes into account the issues raised. 7 The technique first uses a 'universal' primer to initiate RT. One end of this primer anneals to the polyA tail and during the RT process, a unique sequence tag incorporated in the primer is added to the cDNA. Subsequent amplification with the gene-specific primer and a primer compatible to the unique tag results in exclusive amplification of cDNA even in the presence of contaminating gDNA.
7 In contrast to the b-actin primers, the GAPDH primers shown were designed for amplification in conjunction with the 'universal' primer ( Figure 1b) . The identical sample set was analyzed with each primer pair and two significant factors are apparent. First, the universal system amplifies exclusively from
